Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Dussupt

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Cell Host & Microbe|March 4, 2021
B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodiesSamantha M Townsley, Gina C Donofrio, Ningbo Jian, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
Mbio|August 29, 2025
First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challengeVincent Dussupt, Jaime L Jensen, Paul V Thomas, et al.
Annals of the New York Academy of Sciences|November 16, 2022
Antibodies as drugs-a Keystone Symposia reportJennifer Cable, Erica Ollmann Saphire, Adrian C Hayday, et al.
Journal of Virology|May 15, 2015
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchLindsay Wieczorek, Shelly J Krebs, Vaniambadi Kalyanaraman, et al.
Journal of Virology|July 3, 2023
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus ActivityJaime L Jensen, Rajeshwer S Sankhala, Vincent Dussupt, et al.
Iscience|October 1, 2024
SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activityElizabeth J Martinez, William C Chang, Wei-Hung Chen, et al.
Plos Pathogens|December 8, 2020
RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Plos Pathogens|March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Virus Evolution|September 17, 2021
RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infectionEric Lewitus, Eric Sanders-Buell, Meera Bose, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Cell Host & Microbe|March 4, 2021
B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodiesSamantha M Townsley, Gina C Donofrio, Ningbo Jian, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
Mbio|August 29, 2025
First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challengeVincent Dussupt, Jaime L Jensen, Paul V Thomas, et al.
Annals of the New York Academy of Sciences|November 16, 2022
Antibodies as drugs-a Keystone Symposia reportJennifer Cable, Erica Ollmann Saphire, Adrian C Hayday, et al.
Journal of Virology|May 15, 2015
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchLindsay Wieczorek, Shelly J Krebs, Vaniambadi Kalyanaraman, et al.
Journal of Virology|July 3, 2023
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus ActivityJaime L Jensen, Rajeshwer S Sankhala, Vincent Dussupt, et al.
Iscience|October 1, 2024
SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activityElizabeth J Martinez, William C Chang, Wei-Hung Chen, et al.
Plos Pathogens|December 8, 2020
RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Plos Pathogens|March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Virus Evolution|September 17, 2021
RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infectionEric Lewitus, Eric Sanders-Buell, Meera Bose, et al.
Pageof 6